Nektar Therapeutics (NASDAQ:NKTR) has 179 institutional investors with active 13F positions as of December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| FMR LLC | 31 Mar, 2026 | 4,303,188 | 4,202,059 | 4,155.15% | $309,614,403.00 |
| BVF INC/IL | 31 Mar, 2026 | 2,559,595 | 1,000,000 | 64.12% | $184,162,860.00 |
| Two Seas Capital LP | 31 Mar, 2026 | 1,959,178 | 1,213,993 | 162.91% | $140,962,857.00 |
| BVF INC/IL | 31 Mar, 2026 | 1,559,595 | 283,000 | 22.17% | $65,939,677.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 1,197,055 | 1,197,055 | 0.00% | $86,128,107.00 |
| VANGUARD GROUP INC | 31 Mar, 2026 | 1,027,089 | 78,442 | 8.27% | $43,425,322.00 |
| TWO SIGMA INVESTMENTS, LP | 31 Mar, 2026 | 930,741 | 457,727 | 96.77% | $66,966,815.00 |
| Two Seas Capital LP | 31 Mar, 2026 | 745,185 | 745,185 | 0.00% | $31,506,422.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 692,650 | 47,043 | 7.29% | $49,836,168.00 |
| Morgan Stanley | 31 Mar, 2026 | 659,387 | 92,966 | 16.41% | $47,442,895.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 645,607 | 36,493 | 5.99% | $27,296,262.00 |
| ARMISTICE CAPITAL, LLC | 31 Mar, 2026 | 596,000 | 328,000 | 122.39% | $25,198,880.00 |
| ARMISTICE CAPITAL, LLC | 31 Mar, 2026 | 578,000 | -18,000 | -3.02% | $41,587,100.00 |
| Invesco Ltd. | 31 Mar, 2026 | 567,458 | 99,299 | 21.21% | $40,828,603.00 |
| Morgan Stanley | 31 Mar, 2026 | 566,421 | -362,730 | -39.04% | $23,948,280.00 |
| Prosight Management, LP | 31 Mar, 2026 | 554,633 | 554,633 | 0.00% | $23,449,883.00 |
| CITADEL ADVISORS LLC | 31 Mar, 2026 | 513,531 | 203,754 | 65.77% | $36,948,555.00 |
| Sofinnova Investments, Inc. | 31 Mar, 2026 | 509,546 | 70,916 | 16.17% | $36,661,835.00 |
| TWO SIGMA INVESTMENTS, LP | 31 Mar, 2026 | 473,014 | 38,777 | 8.93% | $19,999,032.00 |
| Invesco Ltd. | 31 Mar, 2026 | 468,159 | 241,262 | 106.33% | $19,793,774.00 |